AHA-BUCH

PEGylated Protein Drugs: Basic Science and Clinical Applications
-14 %
Der Artikel wird am Ende des Bestellprozesses zum Download zur Verfügung gestellt.

PEGylated Protein Drugs: Basic Science and Clinical Applications

 Ebook
Sofort lieferbar | 1027 Stück | Lieferzeit:3-5 Tage I

Unser bisheriger Preis:ORGPRICE: 220,95 €

Jetzt 190,39 €*

ISBN-13:
9783764386795
Einband:
Ebook
Seiten:
297
eBook Typ:
PDF
eBook Format:
PDF
Kopierschutz:
1 - PDF Watermark
Sprache:
Englisch
Beschreibung:

"PEGylation technology and key applications are introduced by this topical volume. Basic physical and chemical properties of PEG as basis for altering/improving in vivo behaviour of PEG-conjugates such as increased stability, improved PK/PD, and decreased immunogenicity, are discussed. Furthermore, chemical and enzymatic strategies for the coupling and the conjugate characterization are reported. Following chapters describe approved and marketed PEG-proteins and PEG-oligonucleotides as well as conjugates in various stages of clinical development."
Preface: PEGylated protein conjugates: A new class of therapeutics for the 21st century.- Protein PEGylation, basic science and biological applications.- Reactive PEGs for protein conjugation.- Rebridging disulphides: site-specific PEGylation on natural amino acids by sequential bis-alkylation.- Enzymatic techniques for PEGylation of biopharmaceuticals.- The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites.- Protein conjugates purification and characterization.- PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals.- The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol).- Pegfilgrastim - designing an improved form of rmetHuG-CSF.- PEGylation of human growth hormone: strategies and properties.- PEGylated alpha interferons: two different strategies to achieve increased efficacy.-Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout.- Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent.- PEG: an useful technology in anticancer therapy.- Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines
PEGylation technology and key applications are introduced by this topical volume. Basic physical and chemical properties of PEG as basis for altering/improving in vivo behaviour of PEG-conjugates such as increased stability, improved PK/PD, and decreased immunogenicity, are discussed. Furthermore, chemical and enzymatic strategies for the coupling and the conjugate characterization are reported. Following chapters describe approved and marketed PEG-proteins and PEG-oligonucleotides as well as conjugates in various stages of clinical development.